Association study of IL28B: Rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis

Gene

Volumn 513, Issue 2, 2013, Pages 292-296

  Luo, Yueqiu ^a,b   Jin, Caixia ^c   Ling, Zongxin ^a   Mou, Xiaozhou ^a   Zhang, Qiong ^a   Xiang, Charlie ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

HCV genotype 1; Meta analysis; Polymorphism; Rs12979860; Rs809997; SVR

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN;

ARTICLE; CYTOKINE RESPONSE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENOTYPE; HEPATITIS C; HUMAN; META ANALYSIS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84870758737     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.10.030     Document Type: Article

References (41)

1. Alestig E., et al. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect. Dis. 2011, 11:124.
2. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
3. Chen J.Y., et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011, 12:300-309.
4. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
5. Egger M.D.S.G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997, 315:629-634.
6. Fattovich G., et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment. Pharmacol. Ther. 2011, 33:1162-1172.
7. Fried M.W., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
8. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
9. Ghany M.G., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
10. Halfon P., et al. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur. J. Gastroenterol. Hepatol. 2011, 23:931-935.
11. Hayashi K., et al. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int. 2011, 31:1359-1365.
12. Hayes C.N., et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2010, 60:261-267.
13. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
14. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
15. Huang C.F., et al. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antivir. Res. 2012, 93:239-244.
16. Kurosaki M., et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol. 2011, 54:439-448.
17. Kwon J.H., et al. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J. Intern. Med. 2009, 24:203-211.
18. Liao X.W., et al. Host IL28B and viral genotype differences in responses to antiviral therapy efficacy in chronic hepatitis C. Chin. J. Viral. Dis. 2011, 1:35-40.
19. Lin C.Y., et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6:e18322.
20. Lindh M., et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J. Viral Hepat. 2011, 18:e325-e331.
21. Liu C.H., et al. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir. Ther. 2011, 17:477-484.
22. Mangia A., et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 2011, 54:772-780.
23. Manns M.P., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
24. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
25. Masao H., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509.
26. Mauricio V., et al. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J. Gastroenterol. 2011, 17:3636.
27. McHutchison J.G., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009, 361:580-593.
28. Micallef J.M., et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 2006, 13:34-41.
29. Mw F. Side efects of therapy of hepatitis C and their management. Hepatology 2002, 36:s237-s244.
30. Ogawa, E., et al., in press. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J. Hepatol.
31. Petta, S., F.D., Cammà, C., in press. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir. Ther.
32. Shepard C.W., et al. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
33. Sinn D.H., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J. Gastroenterol. Hepatol. 2011, 26:1374-1379.
34. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
35. Takita M., H.S., Arizumi T. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. Digestion 2011, 84:56-61.
36. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
37. Tatsuo M., et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011, 6:e28617.
38. Thomas D.L., Seeff L.B. Natural history of hepatitis C. Clin. Liver Dis. 2005, 9:383-398.
39. Thompson A.J., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129. (e118).
40. Tolmane I., et al. Interleukin 28B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat. Res. Treat. 2012, 2012:1-4.
41. Toyoda H., K.T., Tada T. Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. J. Med. Virol. 2012, 84:61-70.